Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Li… Read more
Pharmosa Biopharm Inc. (6875) - Net Assets
Latest net assets as of June 2024: NT$1.99 Billion TWD
Based on the latest financial reports, Pharmosa Biopharm Inc. (6875) has net assets worth NT$1.99 Billion TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.22 Billion) and total liabilities (NT$225.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.99 Billion |
| % of Total Assets | 89.85% |
| Annual Growth Rate | 41.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.69 |
Pharmosa Biopharm Inc. - Net Assets Trend (2020–2023)
This chart illustrates how Pharmosa Biopharm Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharmosa Biopharm Inc. (2020–2023)
The table below shows the annual net assets of Pharmosa Biopharm Inc. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.14 Billion | +49.47% |
| 2022-12-31 | NT$761.12 Million | +43.22% |
| 2021-12-31 | NT$531.43 Million | +30.95% |
| 2020-12-31 | NT$405.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmosa Biopharm Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 47074300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$8.46 Million | 0.74% |
| Common Stock | NT$586.02 Million | 51.51% |
| Other Comprehensive Income | NT$6.00K | 0.00% |
| Other Components | NT$543.17 Million | 47.74% |
| Total Equity | NT$1.14 Billion | 100.00% |
Pharmosa Biopharm Inc. Competitors by Market Cap
The table below lists competitors of Pharmosa Biopharm Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
$93.83 Million |
|
CH Biotech R&D Co., Ltd.
TW:6534
|
$93.83 Million |
|
Circus SE
XETRA:CA1
|
$93.85 Million |
|
Gamehost Inc
PINK:GHIFF
|
$93.87 Million |
|
Asia Plus Group Holdings PCL
BK:ASP
|
$93.67 Million |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
$93.65 Million |
|
Nextensa NV
BR:NEXTA
|
$93.65 Million |
|
Fiera Milano SpA
F:FM3
|
$93.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmosa Biopharm Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 761,117,000 to 1,137,653,000, a change of 376,536,000 (49.5%).
- Net income of 8,456,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 368,079,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$8.46 Million | +0.74% |
| Other Comprehensive Income | NT$1.00K | +0.0% |
| Other Changes | NT$368.08 Million | +32.35% |
| Total Change | NT$- | 49.47% |
Book Value vs Market Value Analysis
This analysis compares Pharmosa Biopharm Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.85x to 4.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$8.32 | NT$40.35 | x |
| 2021-12-31 | NT$6.10 | NT$40.35 | x |
| 2022-12-31 | NT$7.56 | NT$40.35 | x |
| 2023-12-31 | NT$10.03 | NT$40.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmosa Biopharm Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.69%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.17x
- Recent ROE (0.74%) is above the historical average (-31.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -44.77% | 0.00% | 0.00x | 1.34x | NT$-222.28 Million |
| 2021 | -48.26% | 0.00% | 0.00x | 1.10x | NT$-309.62 Million |
| 2022 | -35.02% | 0.00% | 0.00x | 1.05x | NT$-342.62 Million |
| 2023 | 0.74% | 2.69% | 0.24x | 1.17x | NT$-105.31 Million |
Industry Comparison
This section compares Pharmosa Biopharm Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmosa Biopharm Inc. (6875) | NT$1.99 Billion | -44.77% | 0.11x | $93.73 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |